| Title: | The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified |
|---|
| Authors: | ID Čas Slak, Teja (Author)
ID Miceska, Simona (Author)
ID Gašljević, Gorana (Author)
ID Boltežar, Lučka (Author)
ID Kloboves-Prevodnik, Veronika (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,03 MB)
MD5: A8AD1398F2E438E7046399F441E858F0
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  DRO - Association of Radiology and Oncology
 OI - Institute of Oncology
|
|---|
| Abstract: | Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the most common type non-Hodgkin’s lymphoma, where the treatment of relapsed/refractory cases is the major challenge. Programmed cell death protein 1 (PD-1) and its ligand PD-L1 play a crucial role in the negative regulation of the immune response against the disease. The aim of the study was to analyze the expression of PD-1 and PD-L1 on lymphoma cells (LCs) and tumor-immune cells (TICs) and to investigate their correlation with outcome. Samples from 283 patients diagnosed with DLBCL, NOS (both germinal center B cell like [GCB] and non-GCB subtypes) were included in the study. Expression of PD-1 and PD-L1 was determined using double immunohistochemical staining (D-IHC) for PD-1/PAX5 and PD-L1/PAX5 on tissue microarrays. LCs were highlighted by D-IHC to obtain more accurate results. Clinical data and histologic diagnoses were obtained from electronic data records. We correlated clinical characteristics, and PD-1 and PD-L1 expression on LCs and TICs with progression-free survival (PFS) and overall survival (OS). Expression of PD-1 on TICs was observed in 38.4% and on LCs in 8.8% of cases, while PD-L1 was expressed on TICs in 46.8% and on LCs in 6.5% of cases. PD-L1 expression on LCs was more frequent in non-GCB subtype (p = 0.047). In addition, patients with PD-L1 expression on LCs had significantly shorter PFS (p = 0.015), and the expression retained significant in the multivariate model (p = 0.034). PD-L1 was more frequently expressed in LCs of the non-GCB subtype. Additionally, PD-L1 in LCs may predict shorter PFS time. D-IHC staining for PD-L1/PAX5 is a feasible method to assess PD-L1 expression on LCs of DLBCL, NOS patients and can be used to identify patients who may benefit from targeted immunotherapy with checkpoint inhibitors. |
|---|
| Keywords: | diffuse large b-cell lymphoma, immunohistochemistry, cytopathology |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.03.2024 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 99-109, X |
|---|
| Numbering: | Vol. 58, no. 1 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-30472  |
|---|
| UDC: | 616-07 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2024-0010 |
|---|
| COBISS.SI-ID: | 189584899 |
|---|
| Publication date in DiRROS: | 26.06.2026 |
|---|
| Views: | 158 |
|---|
| Downloads: | 71 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
